Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-A445 + Paclitaxel + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-A445 | BGB A445|BGBA445 | OX40 Antibody 14 | BGB-A445 is an activating anti-TNFRSF4 (OX40) antibody that does not block binding to its ligand, OX40L, potentially resulting in increased immune response and anti-tumor activity (Journal for ImmunoTherapy of Cancer 2020;8:699). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Tislelizumab | Tevimbra | BGB-A317|tislelizumab-jsgr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|